NA
Highly rated in
16
conditions

Dr. Neeraj K. Agarwal

1950 Cir Of Hope Dr Office
Salt Lake City, UT
Highly rated in
16
conditions
Specialties:Hematology Oncology | Oncology
Experience:28 Years
Clinical Trials:Currently Recruiting for 6 Trials
Accepts:New PatientsMedicare
Highly rated in
16
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Neeraj K. Agarwal's experience treating your condition:
About Dr. Neeraj K. Agarwal

Neeraj Agarwal is a Hematologist Oncology specialist and an Oncologist in Salt Lake City, Utah. Agarwal has been practicing medicine for over 28 years and is highly rated in 16 conditions, according to our data. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Abdominal Wall Surgery, and Orchiectomy. He is licensed to treat patients in Utah. Agarwal is currently accepting new patients.

His clinical research consists of co-authoring 506 peer reviewed articles and participating in 22 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Neeraj K. Agarwal it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Neeraj K. Agarwal accepts the following insurance:

  •  Ambetter
  •  Molina Healthcare
  •  Montana Health Cooperative
  •  Regence
  •  University of Utah Health
  •  BridgeSpan
Call to see if your plan is accepted.
Locations
1950 Cir Of Hope Dr, Salt Lake City, UT 84103
Background & Education
Graduate Institution
Other, 1995
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in UT
Hospital Affiliations
Brigham City Community Hospital
Cassia Regional Hospital
University Of Utah Hospital
Northeastern Nevada Regional Hospital
South Lincoln Medical Center
Memorial Hospital Of Sweetwater County
Castleview Hospital
Moab Regional Hospital
American Fork Hospital
St George Regional Hospital
Madison Memorial Hospital
Mountain View Hospital
Languages Spoken
English
Hindi
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Recruiting
Publish Date: December 09, 2022
Intervention Type: Drug
Study Drugs: AbemaciclibAbiraterone AcetatePrednisone
Study Phase: Phase 2/Phase 3
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: December 07, 2022
Intervention Type: Drug
Study Drugs: Sacituzumab govitecanSacituzumab govitecan+PembrolizumabIMMU-132+CisplatinIMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)
Enrollment Status: Recruiting
Publish Date: June 10, 2022
Intervention Type: Drug
Study Drugs: CabozantinibPembrolizumab
Study Phase: Phase 2
Molecular Biology of Polycythemia and Thrombocytosis
Enrollment Status: Recruiting
Publish Date: November 01, 2021
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Enrollment Status: Recruiting
Publish Date: March 03, 2021
Intervention Type: Drug
Study Drugs: OlaparibAbiraterone acetatePrednisone
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active, not recruiting
Publish Date: December 08, 2022
Intervention Type: Drug
Study Drugs: TAK-700Bicalutamide
Study Phase: Phase 3
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
Enrollment Status: Active, not recruiting
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Active, not recruiting
Publish Date: September 02, 2022
Intervention Type: Drug
Study Drugs: Cabozantinib S-MalateCrizotinibSavolitinibSunitinib Malate
Study Phase: Phase 2
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active, not recruiting
Publish Date: July 19, 2022
Intervention Type: Other, Drug
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Nonpharmacologic Interventions for Fatigue in Patients With Cancer
Enrollment Status: Active, not recruiting
Publish Date: June 28, 2022
Intervention Type: Behavioral
Study Phase: Phase 2
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Enrollment Status: Active, not recruiting
Publish Date: May 11, 2022
Intervention Type: Drug
Study Drugs: IpilimumabNivolumab
Study Phase: Phase 2
A Phase 1B, Open Label, Dose-finding Study to Evaluate the Safety and Tolerability of Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Enrollment Status: Completed
Publish Date: May 06, 2022
Intervention Type: Drug
Study Drugs: AvelumabCabozantinib
Study Phase: Phase 1
A Phase 1b/2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: February 17, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: August 23, 2021
Intervention Type: Drug
Study Drugs: CB-839Cabozantinib
Study Phase: Phase 2
An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: April 23, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
Enrollment Status: Completed
Publish Date: October 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)
Enrollment Status: Terminated
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
Enrollment Status: Completed
Publish Date: October 15, 2019
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
A Neoadjuvant, Randomized, Phase II Study of Vascular Endothelial Growth Factor (VEGF) Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
Enrollment Status: Completed
Publish Date: December 12, 2018
Intervention Type: Other, Drug
Study Phase: Phase 2
View 16 Less Clinical Trials -
506 Total Publications
KIT as a therapeutic target in neuroendocrine prostate cancer.
Journal: Cancer cell
Published: November 04, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
WA
Dr. Wallace L. Akerley
Oncology | Infectious Disease | Hematology Oncology
Highly rated in
17
conditions
Oncology
Infectious Disease
Hematology Oncology

University of Utah Health

Huntsman Cancer Hospital

1950 Circle Of Hope Dr, 
Salt Lake City, UT 

Wallace Akerley is an Oncologist and an Infectious Disease expert in Salt Lake City, Utah. Akerley has been practicing medicine for over 42 years and is highly rated in 17 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. He is licensed to treat patients in Utah. Akerley is currently accepting new patients.

MG
Dr. Martha J. Glenn
Oncology | Hematology Oncology
Highly rated in
28
conditions
Oncology
Hematology Oncology

University of Utah Health

Huntsman Cancer Hospital

1950 Circle Of Hope Dr, 
Salt Lake City, UT 

Martha Glenn is an Oncologist and a Hematologist Oncology expert in Salt Lake City, Utah. Glenn has been practicing medicine for over 34 years and is highly rated in 28 conditions, according to our data. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. She is licensed to treat patients in Utah. Glenn is currently accepting new patients.

SG
Dr. Sumati V. Gupta
Oncology | Geriatrics | Hematology Oncology
Highly rated in
15
conditions
Oncology
Geriatrics
Hematology Oncology

University of Utah Health

Huntsman Cancer Hospital

1950 Circle Of Hope Dr, 
Salt Lake City, UT 

Sumati Gupta is an Oncologist and a Geriatrics expert in Salt Lake City, Utah. Gupta has been practicing medicine for over 26 years and is highly rated in 15 conditions, according to our data. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), and WT1-Related Wilms Tumor Syndromes. She is licensed to treat patients in Utah. Gupta is currently accepting new patients.